Document is current
Any future updates will be listed below
-
Authors
Zinzani, Pier Luigi
Williams, Rhys
Xue, Mei
Neupane, Binod
Zuchinali, Priccila
Fahrbach, Kyle
Burnett, Heather
Sadic, Dennis
Mohseninejad, Leyla
Yang, Keri
-
Funding
Funding for this research was provided by:
BeOne Medicines Ltd.
- License Information
-
More Information
Article History
Received: 10 December 2025
Accepted: 13 February 2026
First Online: 7 March 2026
Declarations
:
: Pier Luigi Zinzani is affiliated with the University of Bologna and IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy; consultant with AstraZeneca, Novartis, MSD, and BeOne Medicines; and attending advisory boards for AstraZeneca, BeOne Medicines, BMS, Eli Lilly, Generon, Incyte, Janssen-Cilag, Kyowa Kirin, MSD Pharma, Novartis, Roche, Sandoz, Secura Bi, SOBI, Takeda, Kite Gilead, Reccordata, and ADS Therapy. Binod Neupane, Priccila Zuchinali, Kyle Fahrbach, and Heather Burnett are employed by Evidera, which has received research funding from BeOne Medicines. Rhys Williams, Mei Xue, Dennis Sadic, Leyla Mohseninejad, Keri Yang are employed by and hold stock options for BeOne Medicines.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.
